Market research
LH Laboratory Corporation of America Holdings
NYSE USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 28B
- P/E ratio
- 27.86
- Analyst target
- 341.5
- Dividend yield
- 0.8%
- Beta
- 0.84
Profile
Company facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US5049221055
- Market cap
- 28B
- P/E ratio
- 27.86
- Analyst target
- 341.5
- Dividend yield
- 0.8%
- Beta
- 0.84
About
About Laboratory Corporation of America Holdings
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the LH discussion.
5 years, 4 months ago
Laboratory Corporation of America Holdings is currently in a long term uptrend where the price is trading 19.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.8.
Laboratory Corporation of America Holdings's total revenue rose by 52.0% to $4B since the same quarter in the previous year.
Its net income has increased by 313.2% to $938M since the same quarter in the previous year.
Finally, its free cash flow grew by 52.9% to $675M since the same quarter in the previous year.
Based on the above factors, Laboratory Corporation of America Holdings gets an overall score of 5/5.